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SUMMARY 
60 Schizophrenic patients were given LiCo3/Chlorpromazine for 4 weeks, in a double blind cross 
over study with two placebo crossovers of 1 week before and two weeks after active treatment. Several core 
schizophrenic featrues showed significant reduction in severity with lithium. However, CPZ tretament was 
superior in terms of improvement, as compared to the other group on MBPRS and CGIS. Target symptoms 
may be one situation, where lithium could be tried and these results are discussed. 
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Several anecdotal studies have exam-
plified the successful use of Lithium in 
Schizophrenia and have hence triggered 
of a running debate regarding its use in 
these disorders (Cade, 1949 ; Garrere and 
Pochard, 1954 ; Glesinger, 1954 ; Mar-
gulies, 1955 ; Rice, 1956 ; Annel, 1969 ; 
Sikes and Sikes, 1970). Others have opined, 
that although lithium does not control the 
underlying schizophrenic process, it does 
help overactivity which is often an asso-
ciated feature of this illness (Gershon and 
Yuwiler, 1960 and Gershon, 1968). Other 
successful uses have been demonstrated in 
infantile psychoses (Gram and Rafaelsen, 
1972) and aggressive behaviour (Dostal 
and Zvotsky, 1970 ; Sheard, 1971 and 
Tupin et al., 1973). Lithium has been 
used successfully as an adjunct to the treat-
ment of chronic schizophrenia in open 
and double blind studies (Meiers, 1970 ; 
Teber, 1970 ; Small et al., 1975 ; Vanputten 
and Sanders, 1975 ; and Growe et al.. 1979). 
Alexander et al. (1979) in a six week study 
between lithium and two placebo cross-
overs demonstrated a reduction in psychosis 
in nine patients. Although none were 
asymptomatic while on lithium, seven 
worsened when lithium was withdrawn. 
Improvement in core schizophrenic symp-
toms, i.e. disordered thought and speech 
were demonstrated in an extension of the 
above study (Van Kammen and Defraites 
1979). Lithium was also found bene-
ficial in periodic catatonia (Gjessing, 
1967) ; Takahashi and Gjessing, 1972 ; 
Petursson, 1976 and Wald and Lerner, 
1976). On the other hand lithium has 
been contraindicated in schizophrenia by 
several workers (Hekimian et al. 1969 ; 
Johnson, 1970 ; Hollister, 1972). Shopsin 
et al., (1971) and Shopsin, (1973) go on 
to say that not only does lithium worsen 
schizophrenic symptomatology but also 
precipitates neurotoxicity. A perusal of 
literature thus reveals conflicting results 
as regards the position of lithium in schizo-
phrenia and the ambiguities sutrounding 
this issue contribute to the difficulty in 
delineating lithium's therapeutic usefulness. 
AIM 
To evaluate the efficacy of lithium 
carbonate as an anti-psychotic agent in 
schizophi'enia. 
SAMPLE AND METHODOLOGY 
60 male schizophrenics (Hebephrenic, 
Catatonic, Paranoid, Residual) diagnosed 
according to LCD.-IX (1977) were taken 
up for the study after a written informed 
consent. The exclusion criteria were : age 
(<20 yrs. or750 yrs., physical illness 
contraindicating lithium, OBS, drug/alcohol 
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addiction, illness reuqiring EGT or other 
forms of treatment and remission in placebo 
period. 
After a detailed psychiatric history, 
clinical examination, and biochemical screen-
ing (pre-lithium) weekly raings were done 
on MBPRS and Clinical Global Impressin 
Scale. Drugs were randomly administered 
i.e. Li/CPZ, in two treatment groups in a 
controlled double blind manner with two 
placebo crossovers of 1 wk before and 2 
weeks after the period of active medication 
which lasted for 4 weeks. Identical capsules 
were used to dispense placebo and drugs. 
Ser. Li. was maintained within the thera-
peutic range and the rater was blind to 
these values. The Mean Ser. Li. level was 
0.65 ±0.2 mEq/1. The most frequent doses 
of Li and GPZ were 991.7 mg/day and 
826.7 mg/day respectively. 
Statistical Analysis : was carried out on 
weekly total scores and individual items of 
the scales, using the Student's 't' test, Chi 
Square test and comparative efficacy of 
the two drugs by analysis of covariance, 
using the initial ratings as covariates for 
each successive ratings. 
OBSERVATIONS 
60 male schizophrenic patients com-
prised the total sample (30 in each group, i.e. 
Li and GPZ). The treatment groups were 
analysed for comparability of age weight, 
and Vaillant's prognostic indicators using 
the Students V test. Xone of the variables 
showed significant differences between the 
two treatment groups The type of onset 
(Criteria of Forrest and Affleck, 1975) 
was analysed using the Chi-Squarc test, 
and no significant difference was found 
between the two groups. 
MBPRS : Baseline mean , ores and 
adjusted mean scores (after analysis of 
covariance) in each week of treatment 
for all items of MBPRS were analysed 
(Table 1). In terms of total scores, Li pro-
duced a significant improvement (pZO.01) 
after 1 week, which increased to highly 
significant levels (p<0.001) from week II 
to week V. CPZ showed highly significant 
improvement (p<0.001) from Wk I till 
end of Wk VI. The items found to be 
highly significant (p<0.001) in terms of 
improvement at any time during Li treat-
ment were : anxiety, emotional withdrawal, 
conceptual disorganization, tension, hostility, 
suspiciousness, hallucinatory behaviour, and 
blunted affect. Somatic concern, depressive 
mood, motor retardation, unusual thought 
content and excitement were influenced at 
lower levels of significance (p<0.01 and 
p<0.05). Guilt feelings, mannerisms and 
posturing, grandiosity, uncooperativeness and 
pressure of speech were not significantly 
influenced at any time by lithium during the 
trial. 
Significant differences in terms of 
improvement between the two treatment 
groups are shown in Table II. 
Lithium was significantly better than 
CPZ on the item of guilt feelings (p<0.001) 
and pressure of speech (p<0.10) after 
week I. After week II, results favoured 
Li on somatic concern (p<0.01) while 
CPZ was superior on the parameters of: 
mannerisms and posturing and pressure of 
speech (p<0.01) ; grandiosity and un-
cooperativeness (p<0.05) and trends 
towards improvement for hostility and sus-
piciousness (p^O.10). For wks III and IV, 
CPZ showed a superior response than Li 
for almost all the items at various levels of 
significance, but for depressive mood 
(p<0.()5) and motor retardation (p<0.10) 
which were favoured by lithium treatment 
at the end of wk. IV. During the treminal 
two placebo weeks, there were trends 
favouring lithium on conceptual disorganiza-
tion, guilt feelings and depressive mood 
while CPZ continued to show significant 
improvement on mannerisms and postur-
ing, pressure of speech, anxiety and trends 
for unusual thought content and con-
ceptual disorganization. Overall, CPZ EFFICACY OF LITHIUM IN SCHIZOPHRENIA 
TABLE I—Adjusted means and significant changes from baseline on MBPRS 
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1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
Item 
Somatic concern 
Anxiety 
Emotional withdrawal 
Conceptual disorgani-
zation. 
Guilt feelings 
Tension 
Mannerisms & Postur-
ing. 
Grandiosity 
Depressive mood 
Hostility 
Suspiciousness 
Hallucinatory Be-
haviour. 
Motor Retardation 
Uncooperativeness 
Unusual thought con-
tent. 
Blunted affect 
Excitement 
Disorientation 
Pressure of Speech .. 
Total Scores 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
L 
C 
BL 
3.50 
3.43 
3.57 
3.20 
4.47 
4.00 
4.37 
4.70 
0.10 
0.27 
1.93 
1.37 
1.80 
1.70 
1.03 
2.17 
1.20 
0.97 
2.47 
3.47 
3.80 
4.40 
3.90 
4.13 
1.90 
0.97 
2.13 
2.87 
4.20 
4.53 
4.00 
3.73 
1.27 
2.27 
0.00 
0.00 
1.73 
3.13 
47.37 
51.33 
After 
I week 
3.10* 
3.20 
3.15 
3.29* 
3.83b 
3.90* 
4.22* 
3.82= 
0.14 
0.23 
1.44 
1.36 
1.59 
1.11b 
1.83 
1.20* 
0.87 
0.96 
2.63 
2.23' 
3.84b 
3.40= 
3.61* 
2.86= 
1.47 
1.53 
2.25 
1.79= 
4.24 
3.86b 
3.47b 
3.60* 
1.4-1* 
1.19' 
0.00 
0.00 
1.81 
2.03 
45.21" 
40.69= 
After 
II week 
2.85b 
2.89 
2.56= 
2.98= 
3.14= 
3.19= 
3.29= 
2.81= 
0.46 
0.12 
0.93b 
0.99b 
1.47 
0.70b 
0.89 
0.70= 
1.00 
0.79 
1.94= 
1.36= 
2.67= 
2.50= 
2.75-
2.09= 
1.16* 
1.47 
1.90 
1.03= 
3.60b 
3.17= 
2.88= 
2.96= 
0.83b 
0.53--
0.00 
0.00 
1.44 
1.06= 
35.60-: 
30.67= 
After 
III week 
2.85* 
2.19= 
2.39= 
2.21b 
2.82= 
2.91= 
3.27= 
2.50= 
0.03 
0.07 
0.73= 
0.81b 
1.40 
0.66= 
1.02 
0.38= 
0.65* 
0.95 
1.99b 
1.11= 
2.85= 
1.85= 
2.41= 
1.69= 
1.01* 
1.32 
1.81 
0.89= 
3.70* 
2.67= 
2.69= 
2.75= 
1.10 
0.30= 
0.00 
0.00 
1.67 
0.66= 
34.77= 
25.33= 
After 
IV week 
2.75* 
1.95= 
2.31= 
1.82= 
2.69= 
2.51= 
3.14= 
1.96= 
0.02 
0.05 
0.79= 
0.74* 
1.41 
0.32= 
0.93 
0.23= 
0.46b 
1.01 
1.74b 
0.83= 
2.68= 
1.48= 
2.20= 
1.40= 
0.91b 
1.39 
1.89 
0.61 = 
3.16 
2.31= 
2.54= 
2.62= 
0.84* 
0.23= 
0.00 
0.00 
1.59 
0.44= 
32.~8= 
21.60-: 
After 
V week 
3.09 
2.60* 
2.65b 
2.55 
3.00= 
3.10= 
3.46= 
2.74= 
0.02 
0.05 
0.88= 
1.22 
1.64 
0.73b 
1.08 
0.62b 
0.75 
0.98 
2.28 
1.86= 
2.80b 
2.63= 
2.38= 
1.82= 
1.16 
1.27 
2.07 
1.56b 
3.5!b 
2.89= 
2.91 = 
2.72= 
1.31 
0.86= 
0.00 
0.00 
2.11 
1.22= 
37.85= 
30.59= 
After 
VI week 
3.62 
3.24 
3.20 
3.13 
3.5 lb 
3.62* 
3.94 
3.19= 
0.03 
0.07 
1.32 
1.62 
2.10 
0.83b 
1.40 
0.80b 
1.18 
1.18 
2.73 
2.37» 
3.27» 
3.06b 
2.79= 
2.24= 
1.33 
1.34 
2.63 
1.97 
3.91 
3.19b 
3.4C* 
3.03b 
1.55 
1.05b 
0.00 
0.00 
2.49 
1.37b 
44.92 
36.78= 
L=Lithium, C=Ghlorpromazine.  = p <0.05, b=p<0.0l c=p<0.001 196 S. DUBE AND B. B. SETHI 
TABLE II—Significant differences betewen lithium and chlorpromazine of MBPRS 
Items 
1. Somatic concern 
2. Anxiety 
4. Conceptual disorganiz-
ation 
5. Guilt Feelings 
7. Mannerisoms & Pos-
turing 
8. Grandiosity 
9. Depressive mood 
10. Hostility 
11. Suspiciousness 
12. Hallucinatory behaviour 
13. Motor Retardation 
14. Uncooperativeness 
15. Unusual thought content 
17. Excitement 
19. Pressure of speech 
Total scores 
After 
I wk. 
, . 
L+ + + 
C + 
c+ 
c+ 
L 
G 
After 
II wk. 
L+ + 
C+ + 
C+ 
C 
G 
C + 
C+ + 
After 
III wk. 
C + 
G 
C + 
C+ + 
G+ 
C+ + 
C 
C + + 
C+ + 
C+ + 
c+ 
C+ + 
After 
IV wk. 
C+ 
C+ + 
G+ + + 
G+ 
L + 
G + 
C+ + 
G + 
L 
C+ + + 
C 
C + 
C+ + 
C+ + 
After 
Vwk. 
G+ 
L 
C+ + 
G 
C + + 
C+ + 
After 
VI wk. 
C 
L 
G+ + + 
L 
G 
C + 
G 
C+=Chlorpromazine significantly better than lithium (p<0.05) 
C+ +—Chlorpromazine significantly better than lihtium (p<0.01) 
C+ + + =Chlorpvomazmc significantly bettre than lithium (p<0.001) 
L+ = Lithium significantly better than chlorpromazine (p<0.05) 
L+ + —Lithium significantly better than chlorpromazine (d<0.01) 
L+ + + —Lithium significantly better than chlorpromazine (p<0.001) 
C=Trends favouring G. P. Z. (p<0.10) ; L=Trends favouring Li. (p<0.10). 
showed a tendency for better improve-
ment on majority of the items during the 
period of the study as compared to lithium. 
GGIS (SEVERITY OF ILLNESS AND GLOBAL 
IMPROVEMENT) 
The baseline mean scores and adjusted 
means (after analysis of covariance) in each 
week of treatment showed highly significant 
improvement in severity of illness with 
lithium (p<0.001) after the II wk to end 
of wk V, and significant improvement 
(p<0.01) after wk VI. Lithium induced 
global improvement was significant at 
p<0.001 after wk II up to wk IV and at 
p<0.01 after wk V. With CPZ improve-
TABLE III—Adjusted means and significant changes from baseline qfCGIS 
Severity of illness 
Global improvement 
.. L 
G 
.. L 
C 
BL 
5.33 
5.43 
• • 
After 
Iwk. 
5.14 
4.67c 
3.73 
3.43 
After 
llwk. 
4.6c 
4.14= 
3.58= 
2-86= 
After 
III wk. 
4.41 = 
3.43= 
3.21
c 
2.62= 
After 
IV wk. 
3.94= 
3.26= 
2.68= 
2.29= 
After 
Vwk. 
4.41= 
4.20= 
3.16b 
2.90b 
After 
VI wk. 
4.53b 
4.57b 
3.61 
3.29b 
L=Lathium ; C=Chlorpromazine ; a=p<0.05 ; b=p<0.01 ; c=p<0.001 EFFICACY OF LITHIUM IN SCHIZOPHRENIA 197 
TABLE IV—Significant differences between lithium andch.krpromaz.int ofCGIS 
After After After After After After 
I wk. II wk. Ill wk. IV wk. V wk. VI wk. 
Severity of illness C + C C++ C + + + 
Global improvemeat .. C+ .. C + 
C+ =Chlorpromazine significantly better than Lithium (p<0.05) 
C+ + =Chlorpromazine significantly better than Lithium (p<0.01) 
C+ + + =Chlorprom&zine significantly better than Lithium (p<0.001) 
ment in severity of illness was similar to 
Li except for persistent effect after Wk VI 
(Table III). 
From wk I till Wk IV, CPZ was sig-
nificantly superior to lithium treatment in 
terms of severity of illness and the global 
improvement with CPZ was better after 
Wk I and III of treatment (Table IV;. 
DISCUSSION 
Lithium response in psychiatric disorders 
has been largely responsible for highlighting 
the enigmas in psychiatric diagnosis. These 
problems, nevertheless, are critical in the 
interpretation of reports relating to thera-
peutic trials. The differential diagnosis 
between pure affective disorders and schizo-
phrenia are largely contributing to the 
contradictory reports relating to lithium 
response in schizophrenia. Most of the 
earlier studies using subjective criteria for 
diagnosis of schizophrenia have confounded 
the issue of therapeutic response. In this 
study, the selection criteria used were 
stringent, are internationally acceptable and 
only "pure" schizophrenics have been 
studied. Since the variables of age, weight, 
Vaillant's prognostic indicators and type of 
onset were not statistically different between 
the two groups, the results are more strongly 
attributable to more specific drug response. 
Observations have revealed that lithium 
influenced not only the non-specific but also 
the core schizophrenic symptoms with a 
characteristic latency of action of lithium 
as compared to CPZ, i.e. from II wk on-
wards. Similar results have also been 
observed by Piien el al. (1972). However, 
some improvement was also witnessed 
during the first week e.g. emotional 
withdrawal, suspiciousness, blunting 
of affect, somatic concern, conceptual dis-
organization, hallucinatory behaviour and 
excitement. Alaxender et al. (1979) have 
also reported that lithium responders show 
signs of improvement during the 1st wk. 
and this response may predict the later 
outcome on lithium. That some parameters 
remain significantly influenced even during 
terminal 2 wks of placebo treatment (wks 
V and VI), is perhaps a reflection of cumu-
lative lithium effect and its gradual ex-
cretion. A remarkably significant feature 
evident from the results was the ineffective-
ness of lithium on so-called "manic 
symptoms" such as grandiosity, pressure of 
speech and elation. Contrarywise, a number 
of workers found improvement in affective 
symptomatology with lithium (Rice, 1956; 
White et al., 1966; Blinder, 1968; Zall et 
al., 1968; Serry 1969; Tupin et al., 1969 
and Sikes and Sikes, 1970). These studies 
however, are contaminated with populations 
of schizo-affective patients and not schizo-
phrenics with affective features. Further, 
these samples were small and the studies 
were open and uncontrolled being subject 
to the error of a personal bias. In keeping 
with the other studies, we found that Li 
effectively controlled hyperactivity, excite-
ment and hostility (Gram and Rafaelsen, 
1972; Martorano, 1972; Tupin et. al., 1973,-198  S. DUBE AND B. B. SETHI 
Small et al., 1975 ; Liebowitz et al., 1976 
and Growe et al., 1979). Li also success-
fully improved withdrawal (motor retarda-
tion) in this study. Growe et al. (1979) 
have reported trends towards less seclusive-
ness and reduced retardation with Li treat-
ment. Indirect evidence towards the same 
is available from studies citing its successful 
use in periodic catatonia. This entity 
howccr, is subject to a nosological confusion 
and has been cited as a variant of affective 
disorder. An important factor contributing 
to the worsening of Shopsin's sample 
(Shopsin et al., 1971) could be attribted to 
development of an organic picture which 
was perhaps a result of high Li dose (Max. 
Li dose =2.0 G, Ser. Li. levels between 
0.65-1.23 m liq/1.). Since most of their 
patients were acutely excited schizophrenics, 
some of them perhaps suffered from transient 
organic psychoses. Simpson et al. (1976) 
who also found poor results had included 
chronic, poor prognosis schizophrenics with 
tardive dyskinesia who might not have 
responded to any neuroleptic medication 
available in our armamentarium at present. 
Lithium therefore, possesses anti-
psychotic properfies and is not a specific 
anti-manic agent. Target sumptoms are 
being increasingly used in therapy with 
developments in neuropsychopharmacology 
and affective rage and hyperactivity appear 
to be related to lithium's therapeutic 
efficacy (Martorano, 1972 ; Growe et al., 
1979\ Animal studies have suggested that 
a combination of Li and neuroleptics may 
offset some of the chronic changes asso-
ciated with neuroleptic induced increased 
dopaminergic receptor activity (Klawans 
et al., 1977). Similar to the hypothesis of 
increased nor-adrenergic activity during 
mania, one can hypothesize that schizo-
phrenic relapse may be associated with 
increased dopaminergic activity (Davis et al., 
197fl\ Following this reasonii g lithium 
could have prophylactic effects upon psy-
chotic relapse in schizophrenia. We do not 
claim lithium tieatment as the drug of 
choice for schizophrenia, nor its superiority 
over CPZ, but it may be that in the coming 
years we are able to clearly delineate the 
characteristic clinical picture of schizo-
phrenics responding to lithium. Lithium 
combined with neuroleptics in chronic neuro-
leptic resistant schizophrenics forms an area 
of promising research. 
ACKNOWLEDGEMENT 
We are thankful to Messrs. May and 
Baker (India) Ltd. for Supplying Chlor-
promazinc Powder for the study. 
REFERENCES 
ALEXANDER, P. E., VAN KAMMEN, D. P. AND BUNNEY, 
VV. E. JR. (1979a). Antipsychotic Effects of 
lithium in schizophrenia. Amer. J. Psychiat. 
136 : 3, 283. 
A.NNEL, A. L. (1969). Lithium in the treatment of 
children and adolescents. Acta. Psychiat. 
Scand., 207 : 19. 
BUNDER, M. (1968). Some observations on the use 
of lithium carbonate. Int. J. Neuropsychiat. 
4, 26. 
CADE, J. F. J. (1949). Lithium salts in treatment 
of psychotic excitement. Med. J. Aust., 2, 36, 
349. 
CARRERE, M. AND POCHARD, A. (1954). Lithium 
carbonate in the treatment of psychomotor 
excitation syndromes. Ann. Med. Psychol. 
112, 566. 
DAVIS, K. L., HOLLISTER, L. E. AND FRITZ, W. C. 
(1978). Neuroleptic induced mesolimbic dopa-
minergic receptor hypersensitivity. Presented 
at 33rd Annual Meeting, Society for Biological 
Psychiatry, Atlanta, Georgia. 
DOSTAL, I. AND ZVOTSKY, P. (1970). A-itiaggressive 
effect of lithium salts in severe mentally retarded 
ad descents. Int. Pharmacopsychiat. 5, 203, 
207. 
GERSHON, S. (1968)1. Use of Lithium Salts in Psy-
chiatric Disorders. Dis. Nerv. Syst., 51. 
GERSHON, S. AND YUWILER, A. (1960). Lithium 
ion : A specific psychopharnvieological ap-
proach to the treatment of mania. Int. J. 
Neuropsychiat. 1, 229. 
GJESSING, L. R. (1967). Lithium citrate loading of a 
patient with periodic catatonia. Acta Psychiat. 
Scand. 43. 372. 
GLESINOER, li. (19541. Evaluation of Lithium in 
treatment of psychotic excitement. Med. J-
Aust., 41. 277. EFFICACY OF LITHIUM IN SCHIZOPHRENIA  199 
GRAM, I.. F. AND RAFAELSEN, O. J. (1972). Lithium 
treatment of Psychotic children and adolescents. 
A controlled clinical trial. Acta, Psychiat. 
Scand., 48, 253. 
GROWE, G. A., CRAYTON, J. W., KLASS, D. B. et al., 
(1979) : Lithium in chro'iic schizophrenia. 
Amer. J. Psychiat., 136 : 4a, 454. 
HEKIMIAN, L. J., GERSHON, S., HARDESTY, A. S., et. 
al. (1969). Drug efficacy and diagnostic spe-
cificity in Manic Depresnve Illness and Schizo-
phrenia- Dis. Nerv. Syst. 30 : 747. 
HOLLISTER, L. E. (1972). Mental Disorders—Anti-
psychotic and Antimanic drugs. New Eng. J. 
Med. 286, 18 : 984. 
JOHNSON, G. (1970). Differential response to lithium 
carbonate in manic depresiive and schizoaffec-
tive disorders. Dis. Nerv. Syst. 31 ; 613. 
KLAWANS, H. L., VVEINER, W. J., NAUSIEDA, P. A. 
(1977). The effect of lithium on an animal 
model of tardive dyskinesia. Prog. Neuropsy-
chopharmac, 1, 53. 
LIEBOWITZ., J. H., RUDY, V., GERSHON, E. S. et al. 
(1976). A Psychopharmacogenetic case report: 
Lithium responsive post psychotic antisocial 
behaviour. Compr. Psychiat. 17(5) : 655. 
MARGULIES, M. (1955). Suggestions for the treat-
ment of schizophrenic and manic depressive 
patients. Med. J. Aust., 42, 137. 
MARTORANO, J. (1972). Target symptoms in lithium 
carbonate therapy. Compr. Psychiat. 13 : 
533. 
MEIERS, R. (1970). Lithium carbonate as adjunct 
in the_ treatment of schizophrenia. Schizo-
phrenia : 2 : 87. 
PETURSSON, H. (1976). Lithium treatment ofa patient 
with periodic catatonia. Acta. Psychiat. Scand., 
54, 248. 
PRIEN, R. F., CAFFEY, JR. E. M. AND KLETT, C. J. 
(1972). A comparison of Lithium carbonate 
and Chlorpromazme in Treatment of Excited 
Schizoaffectives. Arch. Gen. Psychiat., 27, 
182. 
RICE, D. (1956). Use of Lithium salts in the treat-
ment of manic states. J. Meat. Sci. 102, 604. 
SERRY, M. (1969). Lithium excretion test: Clinical 
application and interpretation. Aust. J. Psychiat., 
3, 390. 
SHEAKD, M. H. (1971). Effect of lithium on human 
aggression. Nature. 230: 113. 
SHOPSIN, B. (1973). The use of lithium in schizo-
phrenia. Pjychopharmacol. Bull., 9 : 50. 
SHOPSIN, B., KIM, S. S. AND GERSHON, S. (1971). A 
controlled study of Lithium Vs. Chlorpromazine 
in acute schizophrenics. Brit. J. Psychiat., 119, 
435. 
SIKES, J. C. AND SIKES, S. C. (1970). Lithium carbo-
nate treatment in Psychiatry. Dis. Nerv. Syst. 
31, 52. 
SIMPSON, G. M., BRANCHEY, M. H., LEE, J. H., et al., 
(1976). Lithium in Tardive Dyskinesia. Phar-
makopsychiatry, 9, 76. 
SMALL, J. G., KELLAMS, J. J. AND MILSTEIN, V. et. 
al. (1975). A placebo controlled study of 
Lithium combined with Neuroleptics in chronic 
schizophrenic patients. Amer. J. Psychiat. 132, 
12 : 1315. 
TAKAHASI, S. AND GJESSING, L. R. (1972). Studies 
of periodic catatonia-IV. Longitudinal study of 
catecholamine metabolism, with and without 
drugs. J. Psychiatr. Res. 9. 293. 
TEBER, S. (1970). The effect of lithium salts on some 
psychiatric syndromes. Paper presented at 7th 
Congress of Internationale Neuropsychophar-
macologie, Prague, August, 1970, 
TUPIN, J. P. (1969). Lithium salts : valuable clinical 
drug and research tool, in mental health pro-
gramme reports, Vol. 3, Public Health Service 
Publication No. 1876. Deptt. of Health. Ed. and 
Welfare. 
TUPIN, J., SMITH, D. B., CLANON, T. I. et al. (1973). 
The long term use of lithium in Aggressive 
Prisoners. Compr. Psychiat. 14, 4 : 311. 
VAN PUTTEN, T. AND SANDERS, D. G. (1975). Li-
thium in treatment failures. J. Nerv. Ment. 
Dis., 161, 4 : 255. 
VAN KAMMEN, D. P. AND DEFRAITES, E. G. (1979). 
Lithium treatment in schizophrenia '• A review 
of treatment and prophylaxis in schizophrenia, 
schizoaffective disorders, and periodic cata-
tonia, in Lithium : Controversies and Un-
resolved Issues (eds. ; T. B. Cooper, S. Gershon, 
NS, Kline and M. Schou. Amsterdam, Excerpta 
Medica). 
WALD, D. AND LERNER, J. (1976) : Lithium in the 
treatment of periodic catatonia : A case report. 
Amer. J. Psychiat. 135 : 6, 751. 
WHITE, R. B., SCHLAGENHAUF, G. AND TUPIN J. P. 
(1966). Treatment of manic depressive states 
with lithium carbonate. Curr. Psychiat. Ther ; 
6, 230. 
WORLD HEALTH ORGANIZATION (1977). Manual of 
the International Statistical Classilication of 
Diseases. Injuries and causes of Death. Vol. 1. 
Based on the recommendations of tie Ninth 
Revision Conference, 1975, and adopted by the 
Twenty Ninth World Health Assembly. Geneva, 
W.H.O. 
ZALL, H., THERMAN, P. G. AND MYERS, J. M. (1968). 
Lithium Carbonate : A Clinical study. Amer. J. 
Psychiat. 125, 4, 549. 